Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy

被引:18
|
作者
Abuqbeitah, Mohammad [1 ]
Demir, Mustafa [1 ]
Uslu-Besli, Lebriz [1 ]
Yeyin, Nami [1 ]
Sonmezoglu, Kerim [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Fac Med, Dept Nucl Med, Istanbul, Turkey
关键词
Lu-177-DOTATATE; Lu-177-PSMA; Radiation exposure; Dose rate; Blood clearance; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; RECEPTOR;
D O I
10.1007/s00411-017-0721-6
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The main target of this work is to examine blood clearance and external exposure for Lu-177-DOTATATE compared with new emerging Lu-177-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 +/- 1.1 GBq Lu-177-DOTATATE were compared to those of 23 patients treated with 7.4 GBq Lu-177-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to Lu-177-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 +/- 2.8 and 2 +/- 1.9 A mu Sv/(h GBq), respectively, while those due to Lu-177-PSMA were 3.1 +/- 0.8 and 2.2 +/- 0.9 A mu Sv/(h GBq). Total effective dose of 17 caregivers was 100-200 A mu Sv for Lu-177-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 A mu Sv per patient, respectively, while those for physicists and physicians were 2 A mu Sv per patient. For Lu-177-DOTATATE, effective half-life in blood and early elimination phase were 0.31 +/- 0.13 and 4.5 +/- 1 h, while they were found as 0.4 +/- 0.1 and 5 +/- 1 h, respectively, for Lu-177-PSMA. The first micturition time following Lu-177-DOTATATE infusion was noted after 36 +/- 14 min, while the second and third voiding times were after 74 +/- 9 and 128 +/- 41 min, respectively. It is concluded that blood clearance and radiation exposure for Lu-177-DOTATATE are very similar to those for Lu-177-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 A mu Sv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 A mu Sv/h) after 6 h at 1 m distance.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [21] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Herrmann, Ken
    Kratochwil, Clemens
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
  • [22] 177Lu-PSMA radio-ligand therapy
    Chanchou, M.
    Giraudet, A. L.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2023, 47 (06): : 316 - 322
  • [23] In-vivo stability of 177Lu-DOTATATE during peptide receptor radionuclide therapy
    Wilking, H.
    Ilan, E.
    Sandstrom, M.
    Andersson, C.
    Ost, A.
    Velikyan, I.
    Fross-Baron, K.
    Sundin, A.
    Lubberink, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S592 - S592
  • [24] Biphasic exponential dosimetry model for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Chen, Sirong
    Cheng, Kam
    Li, Ka Chun
    Leung, Yim Lung
    Cheung, William
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [25] Targeted Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Alters Joints Inflammation
    Usmani, Sharjeel
    Rasheed, Rashid
    Ahmed, Najeeb
    Omar, Yehia
    Numani, Shah P.
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (02) : e102 - e104
  • [26] Preliminary results of 177Lu-DOTATATE radionuclide therapy in patients with medullary thyroid cancer
    Lobo Lopes, F. P. P.
    Vaisman, F.
    de Souza Machado Neto, L.
    de Castro, P. H. R.
    Bulzico, D. A.
    Vilhena, B.
    Carneiro, M.
    Corbo, R.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [27] Establishing a clinical dosimetry protocol for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Bissell, S.
    Ross, E.
    McMeekin, H.
    Seal, E.
    Ogunwale, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S106 - S106
  • [28] Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid
    Simsek, Duygu Has
    Kuyumcu, Serkan
    Agaoglu, Fulya Yaman
    Unal, Seher Nilgun
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 764 - 766
  • [29] 177Lu-DOTATATE: comparative study between 177Lu NRG/Netherlands and 177Lu ORNL/USA
    Caldeira Filho, Jose de Souza
    NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 691 - 692
  • [30] 177LU-DOTATATE IN PATIENTS WITH RECURRENT MENINGIOMA
    Nasrollahi, Elham
    Drappatz, Jan
    NEURO-ONCOLOGY, 2024, 26